Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Interest & Investment Income (2019 - 2025)

Harvard Bioscience (HBIO) has disclosed Interest & Investment Income for 7 consecutive years, with -$2.4 million as the latest value for Q4 2025.

  • Quarterly Interest & Investment Income fell 99.83% to -$2.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.9 million through Dec 2025, down 39.06% year-over-year, with the annual reading at -$4.9 million for FY2025, 39.06% down from the prior year.
  • Interest & Investment Income for Q4 2025 was -$2.4 million at Harvard Bioscience, down from -$966000.0 in the prior quarter.
  • The five-year high for Interest & Investment Income was -$373000.0 in Q3 2021, with the low at -$2.4 million in Q4 2025.
  • Average Interest & Investment Income over 5 years is -$806600.0, with a median of -$792500.0 recorded in 2023.
  • The sharpest move saw Interest & Investment Income surged 69.42% in 2021, then crashed 153.65% in 2023.
  • Over 5 years, Interest & Investment Income stood at -$379000.0 in 2021, then crashed by 137.47% to -$900000.0 in 2022, then grew by 11.78% to -$794000.0 in 2023, then crashed by 48.61% to -$1.2 million in 2024, then tumbled by 99.83% to -$2.4 million in 2025.
  • According to Business Quant data, Interest & Investment Income over the past three periods came in at -$2.4 million, -$966000.0, and -$791000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.